Navigation Links
CDC Issues Guidance on Daily Pill to Prevent Infection With HIV
Date:1/27/2011

By Amanda Gardner
HealthDay Reporter

THURSDAY, Jan. 27 (HealthDay News) -- U.S. health authorities on Thursday issued an "interim guidance" to help doctors and patients using Truvada, the once-a-day combination pill that was shown in November to help prevent the spread of HIV in high-risk individuals.

The guidance, from experts at the U.S. Centers for Disease Control and Prevention, stresses that only gay and bisexual men at high risk for contracting the virus -- the same population included in the study -- should use the pill.

When used as a preventive agent, the medication should only be given to men who are currently HIV-negative and only as part of a larger prevention plan that includes testing for other sexually transmitted diseases, counseling and using condoms faithfully.

"While we think this is really a very important new tool in HIV prevention, it has only been proven safe and effective with men who have sex with men, so at this point we don't feel we have the information to discuss its use for anyone other than [this group]," said Dr. Dawn Smith, lead author of the new guidance, which appears in the Jan. 28 issue of the CDC journal Morbidity and Mortality Weekly Report.

Even for highly sexually active gay and bisexual men, "it's not the first line of prevention," Smith said. "It's meant for men who are unable to successfully, consistently use standard methods of reducing their risk of acquiring HIV."

In essence, Truvada is "meant to function as a safety net in addition to those methods. So if a man can't use condoms consistently then maybe [Truvada] would be helpful while they improve condom use," Smith said.

Truvada is a combination of two anti-HIV drugs, emtricitabine (Emtriva) and tenofovir (Viread), included in a once-a-day pill. The pill is already available by prescription as a treatment for HIV infection.

A study published Nov. 25 in the New England Journal of Medicine found that it cut the risk of HIV infection by almost 44 percent in those at highest risk for contracting the virus, namely sexually active gay and bisexual men.

The risk reduction climbed to nearly 73 percent among study participants who took the pill 90 percent of the time, the researchers added.

Both the treatment and the control group in the study also received intensive counseling on safe sex practices and were given condoms (about 500,000 condoms were distributed throughout the course of the trial).

Men in the study reported having had an average of 18 sexual partners in the previous 12 weeks.

Another expert agreed, however, that Truvada is not meant to supplant the condom.

"There has always been a concern that people will see this as an either/or proposition [pill or condom] but it's clearly 'and,'" said Dr. Michael Horberg, director of HIV/AIDS at Kaiser Permanente Health Plan.

"A lot of organizations such as ours have strategized how best to interpret the study results and we totally agree with the considerations of the CDC," he said.

At the time the study was released, the CDC issued "immediate cautions" with similar but less specific recommendations.

This interim report includes more specific information, including getting tested and receiving safe-sex counseling every two to three months while on the medication.

The guidance is intended to fill a gap until formal U.S. Public Health Service guidelines are issued hopefully later this year, Smith said.

"We're working on the first draft of the formal guidelines but, because they involve other Health & Human Services agencies and a public comment process, we don't expect them until later this year," said Smith, who is a biomedical intervention implementation officer at the U.S. National Center for HIV/AIDS Prevention, part of the CDC.

One cloud in the silver lining: A year's worth of Truvada totals more than $10,000 a year, and that is the discounted rate. Generic versions are available in some countries (not the United States) for as low as $500 a year.

More information

There's more on HIV/AIDS at the CDC.

SOURCES: Dawn Smith, M.D., biomedical intervention implementation officer, National Center for HIV/AIDS Prevention, CDC; Michael Horberg, M.D., director, HIV/AIDS, Kaiser Permanente Health Plan; Jan. 28, 2011, Morbidity and Mortality Weekly Report


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Majority of Americans Approve of President Obamas Handling of Afghanistan and National Security But Disapprove of Handling of Economic Issues, Per Franklin & Marshall College Poll With Hearst Television
2. American Red Cross Issues One-Month Progress Report for Haiti Earthquake
3. New study suggests stem cells sabotage their own DNA to produce new tissues
4. One in Two Children Has Chronic Health Issues
5. The Ensign Group Reports Fourth Quarter 2009 Adjusted Earnings of $0.43 Per Share; Issues 2010 Guidance
6. FDA Issues Warning on Key Asthma Drugs
7. Toyota Recalls Raise Awareness of Vehicle Safety Issues, Risks of Accidents from Driving Defective Automobiles
8. CHIME Issues Comments on EHR Incentive Program
9. Americans Weigh in on Skincare Issues
10. Illinois State Senator Cullerton Recognized for Advocacy Work on Mental Health Issues
11. ATS issues statement on disorder of respiratory and autonomic nervous system regulation
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
CDC Issues Guidance on Daily Pill to Prevent Infection With HIV
(Date:9/21/2017)... Renton, WA (PRWEB) , ... September 21, 2017 ... ... inspection technology using Microscan’s LVS 7510 at the Global GS1 Healthcare Conference 2017 ... need of the life-sciences industry for ensuring label quality and improving patient safety. ...
(Date:9/21/2017)... ... September 21, 2017 , ... A new addiction treatment ... a time when Virginia faces an opioid epidemic. , Last year, ... of 38 percent from 2015, underscoring the need for additional addiction treatment options. ...
(Date:9/21/2017)... ... September 21, 2017 , ... In the inaugural 30-minute podcast ... Professor of Education Gregory A. Smith examines student privacy issues with University of ... Schoolhouse Commercialism, Privacy, and the Failure of Policymaking . , Join Smith ...
(Date:9/20/2017)... , ... September 20, 2017 , ... ... one of the Best Places to Work in the Research Triangle for 2017. ... Once nominated, a company had to meet a threshold in employee participation--a percentage ...
(Date:9/20/2017)... ... September 20, 2017 , ... Mirror ... fall event , Look Awesome This Autumn with CoolSculpting®. Scheduled for Thursday, September ... refreshments. , Mirror Mirror Beauty Boutique is Houston’s largest CoolSculpting ...
Breaking Medicine News(10 mins):
(Date:9/1/2017)... Sept. 1, 2017  Bayer will present the latest research ... for Medical Oncology (ESMO) 2017 Congress, September 8-12 in ... new preclinical and clinical data on Bayer,s marketed portfolio and ... projects. "We value ... in cancer research at ESMO," said Carsten Brunn , ...
(Date:8/29/2017)... , Aug. 29, 2017 ivWatch, LLC, the leading provider ... infiltrations, announced it has been awarded an Innovative Technology contract from ... the country. ... device to aid in the early detection of peripheral IV infiltration ... The Innovative Technology contract ...
(Date:8/28/2017)... , Aug. 28, 2017 Hill-Rom Holdings, Inc. (NYSE: ... on Monday, September 11, 2017, in New York ... executive officer, is scheduled to present at 11:05 a.m. Eastern ... accessed at http://ir.hill-rom.com/events.cfm . A recorded replay will be ... through December 10, 2017. ...
Breaking Medicine Technology: